The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease

被引：0
|
作者：
Lars Holger Ehlers
Mark Lamotte
Sofia Monteiro
Susanne Sandgaard
Pia Holmgaard
Evan C. Frary
Niels Ejskjaer
机构：
[1] Aalborg University,Department of Clinical Medicine
[2] IQVIA Real World Solutions,Steno Diabetes Center North Denmark
[3] IQVIA Real World Solutions,Department of Endocrinology
[4] Boehringer Ingelheim Danmark A/S,undefined
[5] Aalborg University Hospital,undefined
[6] Aalborg University Hospital,undefined
来源：
Diabetes Therapy | 2021年 / 12卷
关键词：
Cardiovascular outcomes; Cost-effectiveness; Diabetes type 2; Empagliflozin; Liraglutide;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1523 / 1534
页数：11
相关论文
共 50 条
  • [21] Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US
    Lee, W. C.
    Conner, C.
    Hammer, M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 897 - 906
  • [22] COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE UK
    Schlueter, M.
    Vega-Hernandez, G.
    Wojcik, R.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A675 - A675
  • [23] THE COST-EFFECTIVENESS OF DULAGLUTIDE VERSUS LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN TAIWAN
    Lin, H.
    Babineaux, S.
    Lew, T.
    Lowin, J.
    Lovato, E.
    Strizek, A. A.
    Rajan, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A898 - A898
  • [24] Cost-Effectiveness of Dulaglutide Versus Liraglutide for Management of Type 2 Diabetes Mellitus in Iran
    Ekhlasi, Mahna
    Taheri, Saeed
    Yousefi, Nazila
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2022, 32 : 54 - 61
  • [25] COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN
    Ramirz de Arellano, A.
    Hunt, B.
    Mezquita Raya, P.
    Briones, T.
    Perez, A.
    Valentine, W. J.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A249 - A250
  • [26] COST-EFFECTIVENESS OF EXENATIDE ONCE WEEKLY VERSUS INSULIN GLARGINE AND LIRAGLUTIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Tzanetakos, C.
    Bargiota, A.
    Kourlaba, G.
    Maniadakis, N.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [27] LIRAGLUTIDE VERSUS DAPAGLIFLOZIN FOR THE TREATMENT OF PATIENTS WITH TYPE-2 DIABETES MELLITUS IN SPAIN: A COST-EFFECTIVENESS ANALYSIS
    de Arellano Serna, Ramirez A.
    Mezquita-Raya, P.
    Vega-Hernandez, G.
    Wojcik, R.
    Schlueter, M.
    [J]. VALUE IN HEALTH, 2016, 19 (07) : A674 - A674
  • [28] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AT HIGH CARDIOVASCULAR RISK IN POLAND
    Pawlik, D.
    Wojcik, R.
    Zawodnik, A.
    Kaczor, M. P.
    [J]. VALUE IN HEALTH, 2017, 20 (09) : A478 - A478
  • [29] COST-EFFECTIVENESS ANALYSIS OF EMPAGLIFLOZIN IN COMPARISON TO LIRAGLUTIDE BASED ON CARDIOVASCULAR OUTCOME TRIALS
    Lamotte, M.
    Ramos, M.
    Salem, A.
    Ustyugova, A., V
    Hau, N.
    Gandhi, P.
    Foos, V
    [J]. VALUE IN HEALTH, 2018, 21 : S131 - S131
  • [30] CELESTIA: Cost-Effectiveness Analysis of Empagliflozin Versus Sitagliptin in Patients with Type 2 Diabetes in Greece
    Ghetti, Gianni
    Pradelli, Lorenzo
    Papageorgiou, Giannis
    Karpouzos, George
    Arikan, Yelda
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 97 - 109
12345